FTC Release: FTC Takes Action to Protect Americans from Higher Drug Costs in Aurobindo, Lannett Deal
Dow Jones
Jul 03
Proposed FTC order requires divestiture of four drug products to resolve anticompetitive concerns
The Federal Trade Commission took action to protect American patients from higher drug costs by requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.